


Total Synthesis of a Potent Immunosuppressant Pironetin

Mukund K Gurjar*, John T Henri Jr, D Subhas Bose and A V Rama Rao
 Organic Division III, Indian Institute of Chemical Technology, Hyderabad 500 007, India

Abstract : Total synthesis of PA-48153C Pironetin - a potent immunosuppressant is described. Copyright © 1996 Elsevier Science Ltd

Two Japanese groups simultaneously reported¹ the isolation of Pironetin (PA-48153C) from the fermentation broths of *Streptomyces prunicolor* PA-48153 and *Streptomyces sp.* NK 10958. Pironetin (**1**) showed the plant growth regulator as well as immunosuppressive activity². However, more importantly the mode of action of **1** which is different from those of established immunosuppressants cyclosporin A (CsA) and FK-506, makes pironetin an attractive target for studies. CsA and FK-506 both antagonise T cell activation³ whereas **1** inhibits both T and B lymphocytes to mitogens. Due to severe renal toxicity of CsA and FK-506, there is a need to locate new immunosuppressants with different mechanism of action and pironetin (**1**) offers an ideal candidature. The basic limitation with Pironetin is its cytotoxicity and recent efforts to reduce toxicity by chemical modification⁴ of parent structure was quite promising. In addition, being a simple structure compared to CsA and FK-506, such structural modifications are indeed feasible with **1**.


Since nothing was known about the absolute stereochemistry of pironetin, we embarked on its total synthesis⁵, not only to provide its correct stereostructure but also to develop a synthetic strategy which could be adopted for the preparation of its analogues in order to conduct structure-activity relationship.



We initiated the synthesis of **1** by route A in which the Stork-Ueno radical cyclisation⁶ formed the basic premise of our strategy. The free OH group of methyl (S)-3-hydroxy-2-methylpropionate (**2**) was protected (BnO-C(=NH)-CCl₃, TfOH (cat.), CH₂Cl₂, RT) as benzyl ether derivative **3** (95%) (Scheme 1). Conversion of **3** into the corresponding allylic alcohol (**4**) was a high yielding three step synthetic sequence involving i)

partial reduction with DIBAL-H (C_6H_6 , -78°), ii) Wittig olefination ($Ph_3P=CHCO_2Et$, C_6H_6 , RT) and iii) DIBAL-H reduction (CH_2Cl_2 , -20° -RT). Sharpless asymmetric epoxidation⁷ (TBHP, TTIP, CH_2Cl_2 , -20°) of **4** using (-)-DIPT as a chiral auxiliary provided the epoxy alcohol (**5**) (80%) with 95% ee (HPLC analysis). A one pot conversion of **5** into the optically pure allylic alcohol (**6**)⁸ was conveniently effected at room temperature by reacting with Cp_2TiCl_2 - $ZnCl_2$ -Zn in THF⁹. The 1H -NMR spectrum of **6** was consistent with the structure.

Scheme 1




a) (i) $BnOC(=NH)CCl_3$, TfOH (Cat.), CH_2Cl_2 , RT, 15 h; (ii) DIBAL-H, C_6H_6 , -78° , 30 min., (iii) $Ph_3P=CHCO_2Et$, C_6H_6 , RT, 3 h; (iv) DIBAL-H, CH_2Cl_2 , -20° -RT, 30 min; (b) TBHP, TTIP, (-)-DIPT, CH_2Cl_2 , -20° , 20 h; (c) (i) $(Cp)_2TiCl_2$, $ZnCl_2$, Zn, THF, RT, 1.5 h; (ii) $EtOCH=CH_2$, NBS, CH_2Cl_2 , 0° , 3 h; (d) Bu_3SnH , AIBN, $C_6H_5CH_3$, Δ , 12 h; (e) (i) 80% AcOH, 100° , 1 h; (ii) $Ph_3P=CHCH_3$, $n-BuLi$ (2 eq.), $t-BuOH$, KtOBU, -78° , 1 h; (f) Ph_3P , DEAD, $p-NO_2$, C_6H_4COOH , THF, RT.

Treatment of **6** with ethyl vinyl ether-NBS in CH_2Cl_2 at 0° for 3 h gave the bromoacetal derivative **7** (82%) which was subjected to radical cyclisation under dilute condition (5% solution) using Bu_3SnH -AIBN in refluxing toluene to afford the cyclised product **8** in 70% yield¹⁰. The cleavage of the ethyl acetal group of **8** was conducted in the presence of 80% acetic acid on boiling water bath followed by olefination with $Ph_3P=CHCH_3$ under Schlosser's conditions ($n-BuLi$, $BuOH$, $t-BuOK$, THF, -78°) to afford **9** (35%) whose E-geometry was assigned based on literature precedents^{11,6c}. The next concern was the epimerisation at C_3 (**10**) for which the Mitsunobu reaction (DEAD, TPP, THF, $p-NO_2$ - C_6H_4COOH , RT) was employed. However, the reaction was far from satisfactory in our hands, most of the starting material remained unreacted. Since Wittig and Mitsunobu reactions of route A were not satisfactory to complete the total synthesis of **1**, we felt the need to develop an alternate route which is described below.

Earlier we reported¹² the synthesis of both the isomers of (E)-2-methylhexen-1-ol which was amenable to large scale preparation. The (2S,4E)-isomer (**11**) was successively oxidised¹³ [o-iodoxybenzoic acid (IBX), DMSO, RT], olefinated ($Ph_3P=CHCO_2Et$, C_6H_6 , RT), and reduced (DIBAL-H, CH_2Cl_2 , -20°) to afford the allylic alcohol (**12**) (60% overall yield) (Scheme 2). The Sharpless epoxidation using (-)-DIPT gave the epoxide derivative **13** [$\alpha_D +31.0$ (c 1.5, $CHCl_3$), lit.¹⁴ value for the (-)-enantiomer [$\alpha_D -34.0$ (c 1.3, CH_2Cl_2)]. Subsequently **13** was treated with Me_2CuLi in ether at -78° to give **14** (20:1) whose primary

hydroxyl group was first protected (TBS-Cl, Imidazole, CH₂Cl₂, RT) as TBS-ether followed by methylation (KH, MeI, Et₂O, RT) and deprotection (Bu₄NF, THF, RT) to obtain **15** (80% overall yield). Conversion of **15** into **16** was carried out essentially by the same sequence reported above for compound **12**. The Sharpless epoxidation of **16** with (+)-DIPT as a chiral auxiliary gave **17** (80%) with good diastereoselectivity (92%).

Scheme 2



(a) (i) IBX, DMSO, RT, 30 min., (ii) Ph₃P=CHCO₂Et, C₆H₆, RT, 3 h; (iii) DIBAL-H, CH₂Cl₂, -20^o, 30 min., (b) TBHP, TTIP, (-)DIPT, CH₂Cl₂, -20^o, 20 h, (c) (i) Me₂LiCu, EtOEt, -78^o, 8 h, (II) TBS-Cl, Imid, CH₂Cl₂, RT, 3 h; (iii) KH, MeI, Et₂O, RT, 30 min, (iv) Bu₄NF, THF, RT, 2 h; (d) (i) IBX, DMSO, RT, 30 min; (ii) Ph₃P=CHCO₂Et, C₆H₆, RT, 3 h; (iii) DIBAL-H, CH₂Cl₂, -20^o, 45 min; (e) TBHP, TTIP, (+)DIPT, CH₂Cl₂, -20^o, 18 h; (f) Red-Al, THF, 0^o, 4 h; (g) (i) Piv.Cl, Py, CH₂Cl₂, RT, 1h; (ii) TBS-OTf, 2,6-lutidine, CH₂Cl₂, 0^o, 5 min., (iii) DIBAL-H, CH₂Cl₂, -20^o, 20 min., (iv) IBX, DMSO, RT, 30 min; (h) (S)-N-butanoyloxazolidinone, Bu₂BOTf, CH₂Cl₂, -78^o, 6 h; (i) (i) TBS-OTf, 2,6-lutidine, CH₂Cl₂, 0^o, 10 min., (ii) LiBH₄, MeOH-THF, 0^o-RT, 4h, (j) (i) IBX-DMSO, RT, 30 min; (ii) ((Cl₃CH₂O)₂P=CHCO₂Me, NaH, DMF, -40^o, 6 h; (k) 1% HCl, EtOH, RT, 12 h.

The regioselective reduction (THF, 0^o) of **17** with Red-Al gave 1,3-diol (**18**) (77%) as an exclusive product. By involving protection-deprotection sequence followed by oxidation, **18** was converted into the aldehyde **19** without any difficulty. The Evans aldol condensation¹⁵ of **19** with (S)-N-butanoyloxazolidinone in the presence of dibutylborontriflate at -78^o for 6 h gave **20** with high diastereoselectivity as confirmed by the high resolution ¹H NMR spectrum of the condensed product. At this juncture the free OH group of **20** was protected (TBS-triflate, 2,6-lutidine, CH₂Cl₂, 0^o) and then reduced (LiBH₄, MeOH (1 eq.), THF, 0^o-RT) to give **21** (59% yield)¹⁶. Oxidation (IBX, DMSO, RT) of **21** followed by cis-olefination with modified Horner-Wadsworth-Emmons reaction¹⁷ [(Cl₃CH₂O)₂P=CHCO₂Me, NaH, DMF, -40^o] gave **22** as a sole product,

whose structure was proven by the $^1\text{H-NMR}$ spectrum ($\delta_{\text{H-3}}$ 6.10, $J_{\text{H-2}}$ 5.81, $J_{\text{H2,H3}}$ 11.0 Hz). Finally compound **22** was treated with 1% HCl in EtOH at room temperature for 12 h to give pironetin (**1**) whose m.p., $^1\text{H-NMR}$ spectrum and optical rotation [$[\alpha]_{\text{D}}$ -133 $^{\circ}$, (CHCl_3), lit.^{2,5} -136.6 $^{\circ}$ and -142.8 $^{\circ}$ (CHCl_3)] were identical with the authentic data.

Acknowledgments : One of the authors (JTH) thanks UGC for the financial assistance in the form of fellowship.

REFERENCES AND NOTES

1. a) Yoshida, T.; Koizumi, K.; Kawamura, Y.; Matsumoto, K.; Itazaki, H. *Japan Patent Kokai* 5-310726, **1993**; b) Idem. *European Patent* 560389 A1, **1993**.
2. a) Kobayashi, S.; Tsochiya, K.; Harada, T.; Nishide, M.; Kurokawa, T.; Nakagawa, T.; Shimada, N.; Kobayashi, K. *J. Antibiot.* **1994**, 47, 697; b) Kobayashi, S.; Tsuchiya, K.; Kurokawa, T.; Nakagawa, T.; Shimada, N.; Iitaka, T. *Ibid.* **1994**, 47, 703.
3. Schreiber, S.L.; Albers, M.W.; Brown, E.J. *Acc. Chem. Res.*, **1993**, 26, 412.
4. Yasui, K.; Tamura, Y.; Nakatani, T.; Horibe, I.; Kawada, K.; Koizumi, K.; Suzuki, R.; Ohtani, M. *J. Antibiot.*, **1996**, 49, 173.
5. Yasui, K.; Tamura, Y.; Nakatani, T.; Kawada, K.; Ohtani, M. *J. Org. Chem.*, **1995**, 60, 7567.
6. a) Stork, G.; Mook, R., Jr., Biller, S.A.; Rychnovsky, S.D.; *J. Am. Chem. Soc.*, **1983**, 105, 3741; b) Ueno, Y.; Moriya, O.; Chino, K.; Watanabe, M.; Okawara, M. *J. Chem. Soc., Perkin. Trans. 1*, **1986**, 1351; c) Rama Rao, A.V.; Gurjar, M.K.; Bose, D.S.; Revathi Devi, *J. Org. Chem.*, **1991**, 56, 1320.
7. Katsuki, T.; Martin, V.S. *Organic Reactions*, in press.
8. For obtaining **6**, vinylation of corresponding aldehyde was considered. However, direct vinylation is reported to give threo product (8:1) Still, W.C.; Schneider, J.A.; *Tetrahedron Lett.*, **1980**, 21, 1035.
9. Yadav, J.S.; Shekharam, T.; Gadgil, V.R. *J. Chem. Soc. Chem. Commun.*, **1990**, 843.
10. Compound **8** - $^1\text{H NMR}$ (200 MHz, CDCl_3): δ 0.92 (d, 3H, $J=6.4$ Hz), 1.01 (d, 3H, $J=6.4$ Hz), 1.14 (t, 3H), 1.15-2.4 (m, 4H), 3.25-3.80 (m, 5H), 4.48 (ABq, 2H), 4.90 (d, 1H, $J=4.4$ Hz), 7.28 (s, 5H).
11. Schlosser, M.; Christmann, K.F. *Leibigs Ann. Chem.*, **1967**, 708, 1.
12. Rama Rao, A.V.; Murali Dhar, T.G.; Bose, D.S.; Chakraborty, T.K.; Gurjar, M.K. *Tetrahedron*, **1989**, 45, 7361.
13. Frigerio, M.; Santagostino, M. *Tetrahedron Lett.*, **1994**, 35, 8019.
14. Genet, J.P.; Durand, J.O.; Savignac, M.; Pons, D. *Tetrahedron Lett.*, **1992**, 33, 2497.
15. a) Evans, D.A.; Miller, S.J.; Ennis, M.D.; Ornstein, P.L. *J. Org. Chem.*, **1992**, 57, 1067; b) Evans, D.A.; Rieger, D.L.; Bilodeau, M.T.; Urpi, F. *J. Am. Chem. Soc.*, **1991**, 113, 1047.
16. Compound **21** - $[\alpha]_{\text{D}}$ -40 $^{\circ}$ (c 1.0, CHCl_3): $^1\text{H NMR}$ (200 MHz, CDCl_3): δ 0.08 (s, 12 H), 0.75 (d, 3H, $J=7.0$ Hz), 0.80 (d, 3H, $J=7.0$ Hz), 0.89 (s, 18 H), 0.98 (t, 3H, $J=7.2$ Hz), 1.45-2.25 (m, 9H), 1.66 (d, 3H, $J=5.5$ Hz), 3.14 (brd, 1H), 3.44 (s, 3H), 3.59 (m, 2H), 3.96 (m, 2H), 5.39 (m, 2H).
17. Reddy, M.A.; Gopal, R.J.; Rao, V.J. *Indian J. Chem.*, **1996**, 35B, 312.

IICT Communication No. 3699

(Received in UK 9 July 1996; accepted 19 July 1996)